Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Health

New Market Report Now Available: Francisella Tularensis Infections - Pipeline Review, H2 2013


Print article Print article
2014-01-27 10:26:41 - New Pharmaceuticals market report from Global Markets Direct: "Francisella Tularensis Infections - Pipeline Review, H2 2013"

Global Markets Direct's, 'Francisella Tularensis Infections - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Francisella Tularensis Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Francisella Tularensis Infections. Francisella Tularensis Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Full Report Details at
- www.fastmr.com/prod/769138_francisella_tularensis_infections_pip ..

Note*: Certain sections in the report may be removed or

altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Francisella Tularensis Infections.
* A review of the Francisella Tularensis Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Francisella Tularensis Infections pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to Get this Report

* Identify and understand important and diverse types of therapeutics under development for Francisella Tularensis Infections.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Francisella Tularensis Infections pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned in this Report: Affinium Pharmaceuticals, Ltd., Achaogen Inc., Evolva SA

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Francisella Tularensis Infections Overview
Therapeutics Development
Pipeline Products for Francisella Tularensis Infections - Overview
Pipeline Products for Francisella Tularensis Infections - Comparative Analysis
Francisella Tularensis Infections - Therapeutics under Development by Companies
Francisella Tularensis Infections - Therapeutics under Investigation by Universities/Institutes
Francisella Tularensis Infections - Pipeline Products Glance
Early Stage Products
Francisella Tularensis Infections - Products under Development by Companies
Francisella Tularensis Infections - Products under Investigation by Universities/Institutes
Francisella Tularensis Infections - Companies Involved in Therapeutics Development
Affinium Pharmaceuticals, Ltd.
Achaogen Inc.
Evolva SA
Francisella Tularensis Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Assessment by Therapeutic Class
Drug Profiles
EV-009 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fabl Inhibitor Program - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EV-035 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ACHN-978 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Enoyl Reductase Inhibitors - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Francisella Tularensis Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Enoyl-Reductase Inhibitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Francisella Tularensis Infections - Recent Pipeline Updates
Francisella Tularensis Infections - Dormant Projects
Francisella Tularensis Infections - Product Development Milestones
Featured News & Press Releases
Oct 19, 2011: Tetraphase Receives NIAID Contract Worth Upto $36m For Development Of TP-271
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Francisella Tularensis Infections, H2 2013
Number of Products under Development for Francisella Tularensis Infections - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Early Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Francisella Tularensis Infections - Pipeline by Affinium Pharmaceuticals, Ltd., H2 2013
Francisella Tularensis Infections - Pipeline by Achaogen Inc., H2 2013
Francisella Tularensis Infections - Pipeline by Evolva SA, H2 2013
Assessment by Monotherapy Products, H2 2013

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=769138&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.


Author:
Bill Thompson
e-mail
Web: www.fastmr.com
Phone: 18008448156

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com